Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1978
Size (employees)
7,400 (est)
Website
biogen.com
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People at Biogen

Michel Vounatsos

Michel Vounatsos

CEO

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St

Biogen Data and Metrics

Biogen Financial Metrics

Biogen's revenue was reported to be $2.8 b in Q1, 2017
USD

Revenue (Q1, 2017)

2.8 b

Net income (Q1, 2017)

747.5 m

EBIT (Q1, 2017)

1 b

Market capitalization (18-Aug-2017)

59.8 b

Cash (31-Mar-2017)

924 m
Biogen's current market capitalization is $59.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9 b9.7 b10.8 b11.4 b

Revenue growth, %

40%11%6%

R&D expense

(2 b)

General and administrative expense

(1.9 b)

Operating expense total

(3.9 b)

EBIT

4.9 b5.2 b

EBIT margin, %

45%45%

Income tax expense

1.2 b1.2 b

Net Income

1.9 b2.9 b3.6 b3.7 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

R&D expense

447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

General and administrative expense

576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

Operating expense total

1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m

EBIT

988.7 m1.2 b1.1 b1.2 b1.4 b1.4 b1.5 b1.4 b1 b

EBIT margin, %

41%46%44%48%49%51%50%48%36%

Income tax expense

268.5 m274.8 m281.9 m292.5 m330.1 m356.4 m353.6 m337 m239.2 m

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b

Inventories

659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b

PP&E

1.8 b1.8 b2.2 b2.5 b

Goodwill

1.2 b1.8 b2.7 b3.7 b

Total Assets

11.9 b14.3 b19.5 b22.9 b

Accounts Payable

219.9 m229.2 m267.4 m279.8 m

Total Debt

1.2 b

Current Liabilities

1.8 b2.2 b2.6 b3.4 b

Total Liabilities

10.7 b

Additional Paid-in Capital

4 b4.2 b

Retained Earnings

6.3 b9.3 b12.2 b15.1 b

Total Equity

8.6 b10.8 b9.4 b12.1 b

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.3 x2.1 x1.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

Accounts Receivable

1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Current Assets

3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b

PP&E

1.8 b1.7 b1.7 b1.8 b2 b2.3 b2.3 b2.4 b2.6 b

Goodwill

1.4 b1.5 b1.8 b2.2 b2.4 b2.9 b3.2 b3.4 b3.6 b

Total Assets

12.9 b13.7 b15.2 b16.8 b20.7 b20.7 b21.5 b22.1 b21.2 b

Accounts Payable

224.9 m233.6 m236.1 m282.7 m251.2 m271.3 m225.9 m274 m316.4 m

Current Liabilities

1.9 b1.9 b1.9 b2.6 b2.6 b2.8 b2.5 b2.5 b3 b

Additional Paid-in Capital

4.1 b4.2 b4.2 b4.3 b1.3 b18.4 m69.1 m

Retained Earnings

7.5 b8.4 b10.1 b11 b12 b13.2 b14.2 b15 b14.8 b

Total Equity

9.6 b10.4 b11.7 b12.6 b10.6 b10.3 b11.4 b12.1 b11.5 b

Financial Leverage

1.4 x1.3 x1.3 x1.3 x2 x2 x1.9 x1.8 x1.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Accounts Receivable

(130 m)(510 m)29 m(241.4 m)

Inventories

(240 m)(190 m)(170 m)(165.6 m)

Purchases of PP&E

(246.3 m)(287.8 m)(643 m)(616.1 m)

Cash From Investing Activities

(1.6 b)(1.5 b)(4.6 b)(2.5 b)

Cash From Financing Activities

(716.5 m)(755.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

Accounts Receivable

1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Accounts Payable

282.7 m251.2 m271.3 m225.9 m274 m316.4 m
USDY, 2017

Revenue/Employee

379.8 k

Financial Leverage

1.8 x

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016
FY, 2016

Training Provided, no. of people

40 k

Phase III Trials

2

Phase II Trials

10

Phase I Trials

4

Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Traffic Overview of Biogen

Biogen Online and Social Media Presence

Biogen News and Updates

Here’s Why Investors Weren’t Excited About Biogen’s New CEO

Biogen shares dropped as much as 4.6% on news of his appointment Monday.

Biogen Drug Shows Early Promise against Alzheimer’s Disease

Early results suggest a treatment for root causes, not just symptoms.

Biogen not pursuing a sale: source

(Reuters) - U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.

Biogen Shares Are Spiking On Rumors of a Mega-Deal With Its Rivals

Both Merck and Allergan are reportedly exploring a buyout.

Biogen Company Life and Culture

You may also be interested in